Special Issue "Antibodies Therapies against Infectious Diseases"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 May 2014)
Approximately 30 monoclonal antibodies are currently licensed for use to treat human diseases such as cancer, autoimmune disorders, allergy and transplant rejection. However, just one monoclonal antibody (palivizumab) is licensed that targets an infectious disease pathogen (respiratory syncytial virus, RSV). Nevertheless, several antibodies (approximately 10 of 200) are undergoing preclinical development, or are in clinical trials, for viral infectious diseases. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the art technology and developments in the field of antibody therapies against infectious diseases.
Dr. Gary McLean
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- monoclonal antibodies
- infectious diseases
- clinical trial